HC022

DRUG2 trials

Sponsors

HC Biopharma Inc.

Conditions

Cutaneous Lupus Erythematosus (CLE)Systemic Lupus ErythematosusSystemic Lupus Erythematosus (SLE)

Phase 1

Safety, Tolerability, and Pharmacokinetics of Single Doses of HC022 in Healthy Subjects.

RecruitingNCT06657703

HC Biopharma Inc.Systemic Lupus Erythematosus

Start: 2024-11-25End: 2026-01-08Target: 38Updated: 2025-04-17

The Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HC022 Injection in Subjects With SLE/CLE

Not yet recruitingNCT07306585

HC Biopharma Inc.Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus (SLE)

Start: 2025-12-30End: 2027-09-24Target: 32Updated: 2026-01-28